Osteoporosis Drugs Market Report by Product Type, Route of Administration, Country and Company Analysis 2026-2034

The Osteoporosis Drugs Market is poised to exhibit significant growth owing to the growing incidence of bone-related ailments and the aging population globally. The market is forecasted to grow from USD 18.98 billion in 2025 to USD 27.87 billion by 2034, registering a CAGR of 4.36% during 2026-2034. Awareness about bone health, the development of biological drugs, and the growing preference for preventive treatments are aiding in the growth of the market.

Osteoporosis Drugs Market Outlooks

Osteoporosis drugs refer to therapeutic agents that are used to either manage, treat, or prevent a condition known as Osteoporosis. Osteoporosis is a disease where there is reduced bone mass, which makes one prone to bone fractures. Osteoporosis drugs increase the bone strength by reducing bone loss and enhancing bone formation. Some popular classes of osteoporosis drugs include bisphosphonates, hormones therapy, SERMS, monoclonal antibodies, and bone formers. Examples of osteoporosis drugs that are currently popular include alendronate, denosumab, and teriparatide among others. The popularity of osteoporosis drugs is on the rise globally.

This has been driven by several factors such as the increase in aging population and lifestyle diseases, poor nutrition, and increased awareness about bone health issues. Developed nations such as those in North America and Europe have high osteoporosis drugs market adoption rates due to their advanced healthcare facilities and screening programs. On the other hand, nations in emerging markets such as those in the Asia Pacific region are registering an upsurge in demand for osteoporosis drugs due to improved healthcare systems and diagnosis rate improvements.

Top 10 Countries with Highest Ageing Population Share in 2025

Rank Country / Territory Population Aged 65+ (%) in 2025

• Monaco 36.2%
• Japan 29.8%
• Puerto Rico 24.7%
• Italy 24.6%
• Portugal 24.5%
• Greece 23.9%
• Finland 23.9%
• Germany 23.2%
• Croatia 23.2%
• Serbia 22.7%

Top 10 Countries with Highest Osteoporotic Fracture Burden Worldwide

Rank Country Estimated Osteoporotic Fracture Burden / Prevalence Trend in 2025

• Germany ~936,000 annual osteoporotic fractures
• United Kingdom ~682,000 annual osteoporotic fractures
• Italy ~599,000 annual osteoporotic fractures
• France ~493,000 annual osteoporotic fractures
• Spain ~285,000 annual osteoporotic fractures
• Poland ~209,000 annual osteoporotic fractures
• Sweden ~135,000 annual osteoporotic fractures
• Greece ~105,000 annual osteoporotic fractures
• Netherlands ~108,000 annual osteoporotic fractures
• Czech Republic ~98,000 annual osteoporotic fractures

Growth Drivers of the Osteoporosis Drugs Market

Rising Aging Population and Increasing Osteoporosis Prevalence

The United Nations predicts that the total population aged 65 years and above will grow to 761 million by 2025 from the current figure of 727 million. The rising global geriatric population is one of the key factors fueling the growth of the Osteoporosis Drugs market. Aging is a significant cause of Osteoporosis since bone density is bound to decrease with increasing age, especially in postmenopausal women. With increased life expectancy in most countries around the world, the total number of individuals exposed to bone fractures and other related health complications has increased exponentially. There have been notable increases in geriatric patients within developed nations in North America, Europe, Japan, and developing nations in Asia. Sedentary lifestyle choices, dietary deficiencies in Calcium and Vitamin D, smoking habits, and hormonal imbalances are among the main reasons why the disease burden is on the rise. Health agencies are increasingly focusing on prevention strategies to reduce health expenditures. Screening of bone densities has increased. Thus, demand for Osteoporosis Drugs is expected to be high going forward.

Advancements in Biologic and Bone-Forming Therapies

Advancements in technology and the pharmaceutical industry have been playing a vital role in the expansion of the market for Osteoporosis Drugs. The use of conventional bisphosphonate medicines is increasingly being followed up by biological drugs and bone forming substances that provide superior efficacy. Such medicines include monoclonal antibodies and bone forming medicines that enable patients not just to lose less bone tissue but also generate bone tissue in their body. There is significant investment on the part of pharmaceutical companies in the creation of drugs that can be taken at less frequent intervals along with having fewer side effects. Personalized medicine and target therapies are some other areas that show potential in the management of the disease. Furthermore, the introduction of novel drug delivery techniques, which include the use of injectable biologics and yearly doses of medication, adds to the convenience of the patient. This has led to increased adoption of newer osteoporosis medicines by physicians and health care professionals. Two new biologics, Enoby and Xtrenbo, were introduced by Hikma Pharmaceuticals PLC in January 2026. These two products have been developed from the existing drugs Prolia and Xgeva respectively. The ingredients used in the development of both these medications include denosumab, which is a recombinant human monoclonal antibody (IgG2).

Increasing Awareness and Preventive Healthcare Initiatives

Awareness about bone health and bone fracture is yet another significant driver in the global Osteoporosis Drugs market. Public campaigns and other educational initiatives are helping people realize the importance of getting a bone density test and taking medication. There is an increasing emphasis on preventative treatments among healthcare providers and high-risk groups such as the elderly and post-menopausal women. Growing awareness about the severity of the issue and how bone fractures can lead to disability and poor quality of life has driven the demand for osteoporosis drugs. Moreover, health organizations have also been promoting the concept of nutrition and exercise for good bone health as well as providing information about dietary supplements. Governments in several countries have been working towards providing better insurance coverage and other incentives in order to make it easier for patients to get treated. The growing number of specialty orthopedics clinics and hospitals for osteoporosis diagnosis and treatment has further helped increase the usage of osteoporosis drugs. October 2025, IOF proudly announces that the Build Better Bones website is now equipped with additional information about osteoporosis diagnosis and treatment.

Challenges of the Osteoporosis Drugs Market

Side Effects and Long-Term Safety Concerns

The other major challenge facing the Osteoporosis Drugs industry is that of patient safety and side effects on account of drug use over an extended period of time. Many of the currently marketed drugs against osteoporosis, including the bisphosphonate class of drugs, come with possible side effects like gastrointestinal tract irritations, atypical fractures of the femur, and osteonecrosis of the jaw. Such issues could lead to reluctance amongst patients to continue with the treatment regimen, especially because osteoporosis treatment usually entails a continued intake of medicines for many years together. There is also the danger of doctors becoming wary about prescribing certain drugs to their patients due to fear of side effects. In case of biologics in particular, there could be some risks in terms of immune response and cardiovascular side effects. Such factors make it difficult for patients to comply with the recommended dosage of the medicine.

Underdiagnosis and Limited Treatment Adoption

Although the number of people diagnosed with osteoporosis continues to grow, the problem of underdiagnosis is still widespread in the market. There is no way for many people to know that they suffer from this disease unless they sustain an injury, since osteoporosis develops gradually without causing any outward symptoms. Lack of knowledge about osteoporosis among people in developing countries and inadequate programs for routine testing prevent timely identification and treatment of the disease. Moreover, in some countries, testing for bone mineral density and medical care are difficult to obtain because of lack of facilities in rural or poor urban areas. Some patients also do not take their illness seriously and refuse to take medicines due to fear of spending too much money on treatment or developing side effects. Healthcare systems in certain countries prefer to treat acute illnesses and pay little attention to preventive measures concerning bone health.

Calcitonin Osteoporosis Drugs Market

Calcitonin drugs have been crucial in dealing with Osteoporosis cases where there has been resistance to other forms of treatment. Calcitonin hormones work on the regulation of calcium levels in the body as well as reducing bone resorption. These medications can be taken via nasal sprays and injections, and they are mainly used for postmenopausal women suffering from osteoporosis. The calcitonin osteoporosis drug segment is sustained by its pain relief benefits, especially in people who have spinal fractures, as well as the easy way in which these drugs can be used. Nevertheless, there has been a moderate restriction in the growth rate in this market owing to the presence of more effective drugs available on the market today. The safety issues with these medications and lack of physician support have also contributed to such restrictions. Nonetheless, calcitonin drugs have continued to enjoy steady demand among older patients and those requiring alternative Osteoporosis treatments around the world.

Bisphosphonates Osteoporosis Drugs Market

Among osteoporosis drugs, bisphosphonates have been found to be one of the largest classes in terms of size and prescription frequency. Bisphosphonates help maintain bone density in patients with osteoporosis through inhibition of bone resorption processes. Some common bisphosphonate drugs include alendronate, risedronate, and zoledronic acid, all of which are highly prescribed to postmenopausal women and older individuals that are at high fracture risk. The bisphosphonates market has been largely influenced by the high efficacy, relatively low price, and ease of access to bisphosphonates in healthcare facilities worldwide. Both oral and IV forms of bisphosphonates allow for easier administration of this class of drugs. Besides, healthcare practitioners often prescribe bisphosphonates as a first choice in treating osteoporosis as they are proven safe and effective over the years. Atypical fractures and osteonecrosis of the jaw remain among the potential side effects of prolonged bisphosphonate use that can discourage patients. Nevertheless, despite the emergence of biologics, bisphosphonates remain a dominating market segment in osteoporosis treatment because of low cost and high physicians' acceptance of the drug class.

Sclerostin Inhibitor Osteoporosis Drugs Market

Sclerostin inhibitor is an emerging category that is considered to be advanced in the osteoporosis treatment drugs market. The category is based on the use of inhibitors to block the sclerostin protein and stimulate the formation of bone tissue. It is anticipated that the segment will receive significant interest due to the increase in demand for therapies capable not only of slowing down the process of bone tissue decomposition but also contributing to its formation and enhancement. Moreover, such products are highly effective for patients diagnosed with osteoporosis and at high risks of fractures, who do not benefit from traditional therapy. Companies invest in the development of drugs belonging to this segment, as well as other related biologic products and medications to enhance bone health in patients. This category is influenced by the increased interest of medical practitioners in anabolic therapies as well as developments in biologic drug development. However, one should also note possible constraints such as the high price of treatment and necessity of assessing patients' cardiovascular risk.

Osteoporosis Oral Drugs Market

The osteoporosis oral drugs market is one of the largest markets within the global osteoporosis treatment market owing to the ease of administration of oral medicines. Bisphosphonates and SERMs are the two most common classes of osteoporosis drugs used in first-line therapy regimens. These drugs are well accepted among patients since they can be taken at home without the need for hospitalization or intravenous injections. Growth in this market is attributed to the increasing prevalence of osteoporosis, aging populations, and awareness regarding preventive bone health care. Physicians have a favorable opinion towards oral medicines owing to their cost efficiency and proven effectiveness in lowering fracture rates. Adherence to oral osteoporosis drugs is another issue affecting the growth of this market since some osteoporosis oral drugs must be consumed with strict dose timing and have adverse effects such as nausea and diarrhea. Competition from novel drug products such as injectable biologics has not dented the market share of osteoporosis oral drugs.

United States Osteoporosis Drugs Market

Osteoporosis drugs have gained popularity in the U.S. market due to a higher rate of the disease in the country and the fact that its population is experiencing a faster rate of aging. Awareness of bone health, well-developed healthcare infrastructure, and availability of modern technologies in the field of diagnostics have played an important role in the rapid development of the market. The presence of major pharmaceutical and biotech companies guarantees constant development of biologic products, monoclonal antibodies, and osteogenic medications. Health specialists encourage their clients to conduct preventive diagnostics and treatment among post-menopausal women and old patients prone to fractures. Effective reimbursement systems and high levels of insurance coverages make this medication more affordable. Besides, increased investments into research help develop new, innovative treatments. On February 2025, the U.S. Food and Drug Administration has approved Ospomyv, which is the brand name of Denosumab-dssb as a biosimilar version of Prolia.

United Kingdom Osteoporosis Drugs Market

The UK osteoporosis medication market is experiencing significant growth owing to increased understanding of the effects of aging on bones as well as healthcare concerns regarding bone injuries. The country boasts of having a reliable healthcare system that enables proper identification of the disease and its subsequent management in special centers and screening programs. Public healthcare programs promote routine bone mineral density tests especially in elderly people and post-menopausal women. While oral bisphosphonates continue to be commonly prescribed, the use of biological therapies in treating this condition has been growing slowly among high-risk patients. The government-sponsored guidelines for the treatment and management of the condition play an instrumental role in ensuring wider availability of the drugs. Moreover, there is an emphasis on preventative measures in reducing the costs of osteoporosis and its effects on healthcare systems. On the other hand, healthcare strain and long wait times to see specialists pose challenges in accessing treatment. Abaloparatide, a very potent anabolic drug, is currently recommended by NICE for the treatment of osteoporosis in those with a high risk of fractures. The brand names for abaloparatide include Tymlos, Eladynos, and Ostavaro, and have been increasingly used in the global osteoporosis market owing to their efficacy and physician familiarity.

India Osteoporosis Drugs Market

India represents one of the fastest-growing markets for osteoporosis medications, mainly due to an increase in the geriatric population, lifestyle changes, and nutritional deficiencies. Awareness about osteoporosis and fractures is increasing, which is prompting people to undergo diagnosis and treatment. An increase in investment in private healthcare facilities, specialized hospitals, and diagnostic centers is contributing to easier access to osteoporosis tests and treatments in urban areas. Furthermore, rising healthcare spending and the emphasis on preventive healthcare by the government are fueling market growth. Bisphosphonates in oral form are commonly consumed owing to their affordability; however, there is a slow but steady rise in the demand for biological and injectable drugs among urban residents. Nevertheless, low awareness levels, underdiagnoses, and the expensive nature of some medicines are key barriers to market development. Patients are usually diagnosed only after suffering fractures due to the lack of regular tests. Although some factors inhibit market development, India holds promising prospects in the coming years due to the large number of patients and improvements in the healthcare sector. December 2025, Zydus Lifesciences has launched their Denosumab biosimilar product named “Zyrifa” in India. Zyrifa is the biosimilar version of the highly successful Amgen product Xgeva, which is Denosumab and has received approval for preventing skeletal complications among cancer patients.

Saudi Arabia Osteoporosis Drugs Market

The Saudi Arabian osteoporosis drugs market is experiencing steady growth owing to factors such as improved longevity, lifestyle changes, and greater awareness of diseases that affect bone health. Vitamin D deficiency, obesity, and sedentary lifestyle contribute significantly to higher chances of suffering from osteoporosis in Saudi Arabia, especially among women and older people. Improvements in healthcare facilities through increased investment in state-of-the-art medical infrastructure are enhancing access to diagnosis and treatments related to osteoporosis. The use of modern osteoporosis treatments like injectable biologic drugs and bone formation medicines is gaining traction among hospitals and specialists. The implementation of new policies aimed at reforming Saudi Arabia’s healthcare industry, as well as the involvement of private sector organizations in delivering treatment and medicines for bone health conditions, have positively influenced the pharmaceutical and orthopedic segments. Public campaigns aimed at educating about healthy aging and preventing fractures can further enhance growth prospects in the sector. On the downside, high dependency on imported drugs and their prices can hamper market development.

Osteoporosis Drugs Market Segments

Product Type

• Bisphosphonates
• Calcitonin
• Rank Ligand Inhibitor
• Parathyroid Hormone Therapy (PTH)
• Selective Estrogen Receptor Modulators (SERMs)
• Sclerostin Inhibitor
• Others

Route of Administration

• Oral
• Injectable
• Others

Country

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• Amgen Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.